Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00571662 · OUTCOME

Incidence of Acute and Chronic Graft-versus-host Disease

Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant · Source last updated 2023-10-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percent of Particpants
Interval / dispersion
Not reported
Time frame
twice weekly until day 100 up to 1 year post transplant

What was measured

Incidence of acute and chronic graft-versus-host disease. Acute GVHD usually occurs during the first three months following transplant. Chronic GVHD usually develops after the third month post-transplant.

Groups in this outcome

Cohort I

Pentostatin to be administered intravenously on days -10, -9, and -8 at a dose of 4mg/m2/day

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort I68

Reported measurements

Acute GVHD
Values in Percent of Particpants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort I31Not reportedNot reportedNot reportedNot reported
Chronic GVHD
Values in Percent of Particpants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Cohort I33Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        31
    title
    Acute GVHD
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        33
    title
    Chronic GVHD
denoms
  1. counts
    1. group Id
      OG000
      value
      68
    units
    Participants
description
Incidence of acute and chronic graft-versus-host disease. Acute GVHD usually occurs during the first three months following transplant. Chronic GVHD usually develops after the third month post-transplant.
groups
  1. description
    Pentostatin to be administered intravenously on days -10, -9, and -8 at a dose of 4mg/m2/day
    id
    OG000
    title
    Cohort I
param Type
NUMBER
reporting Status
POSTED
time Frame
twice weekly until day 100 up to 1 year post transplant
title
Incidence of Acute and Chronic Graft-versus-host Disease
type
SECONDARY
unit Of Measure
Percent of Particpants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice